Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-84b7d79bbc-g5fl4 Total loading time: 0 Render date: 2024-07-25T08:54:15.278Z Has data issue: false hasContentIssue false

Chapter 70 - Pharmacologic Controversies in Hematopoietic Cell Transplants

from Section 17 - Novel Cell Therapies and Manipulations: Ready for Prime-Time?

Published online by Cambridge University Press:  24 May 2017

By
Elizabeth C. DiMaggio  and
Helen Leather
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 678 - 696
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Badros, A, Barlogie, B, Siegel, E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–9.Google ScholarPubMed
Raab, MS, Breitkreutz, I, Hundemer, M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica. 2006;91(11):1555–8.Google ScholarPubMed
Knudsen, LM, Nielsen, B, Gimsing, P, Geisler, C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27–33.CrossRefGoogle ScholarPubMed
Dimopoulos, MA, Terpos, E, Chanan-Khan, A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976–84.CrossRefGoogle Scholar
Parikh, GC, Amjad, AI, Saliba, RM, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(7):812–6.CrossRefGoogle ScholarPubMed
Abidi, MH, Agarwal, R, Ayash, L, et al. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biol Blood Marrow Transplant. 2012;18(9):1455–61.CrossRefGoogle ScholarPubMed
Bodge, MN, Reddy, S, Thompson, MS, Savani, BN. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. Biol Blood Marrow Transplant. 2014;20(7):908–19.Google ScholarPubMed
Tricot, G, Alberts, DS, Johnson, C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2(6):947–52.Google ScholarPubMed
Tosi, P, Zamagni, E, Ronconi, S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia. 2000;14:1310–13.CrossRefGoogle ScholarPubMed
Hamaki, T, Katori, H, Kami, M, et al. Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. Bone Marrow Transplant. 2002;30:195–8.CrossRefGoogle Scholar
Lee, CK, Zangari, M, Barlogie, B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33(8):823–8.CrossRefGoogle ScholarPubMed
Termuhlen, AM, Grovas, A, Klopfenstein, K, et al. Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Pediatr Transplant. 2006;10:830–4.CrossRefGoogle ScholarPubMed
de Souza, JA, Saliba, RM, Patah, P, et al. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1094–9.CrossRefGoogle Scholar
Tendas, A, Cupelli, L, Dentamaro, T, et al. Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma. Ann Hematol. 2009;88:285–6.CrossRefGoogle Scholar
Choi, HS, Kim, SY, Lee, JH, et al. Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease. Transplantation. 2011;92:e28–e29.CrossRefGoogle Scholar
van Besien, K, Schouten, V, Parsad, S, et al. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012;53:158–9.CrossRefGoogle ScholarPubMed
Kergueris, MF, et al. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res. 1994;14:2379–82.Google ScholarPubMed
Santos, GW, Tutschka, PJ, Brookmeyer, R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22):1347–53.CrossRefGoogle ScholarPubMed
Tutschka, PJ, Copelan, EA, Klein, JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382–8.CrossRefGoogle ScholarPubMed
Vassal, G, Deroussent, A, Hartmann, O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50(19):6203–7.Google ScholarPubMed
Hassan, M, Oberg, G, Björkholm, M, Wallin, I, Lindgren, M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33(3):181–6.CrossRefGoogle Scholar
Sureda, A, Pérez de Oteyza, J, García Laraña, J, Odriozola, J. High-dose busulfan and seizures. Ann Intern Med. 1989;111(6):543–4.CrossRefGoogle ScholarPubMed
Hamidieh, AA, Hamedani, R, Hadjibabaie, M, et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol. 2010;27(7):529–33.CrossRefGoogle ScholarPubMed
Chan, KW, Mullen, CA, Worth, LL, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002;29(12):963–5.CrossRefGoogle ScholarPubMed
Eberly, AL, Anderson, GD, Bubalo, JS, McCune, JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008;28(12):1502–10.CrossRefGoogle ScholarPubMed
Grigg, AP, Shepherd, JD, Phillips, GL. Busulphan and phenytoin. Ann Intern Med. 1989;111(12):1049–50.CrossRefGoogle ScholarPubMed
Soni, S, Skeens, M, Termuhlen, AM, et al. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2012;59(4):762–4.CrossRefGoogle ScholarPubMed
Bubalo, JS, Kovascovics, TJ, Meyers, G, et al. Clonazepam and levetiracetam for prevention of busulfan-induced seizures: a singer-center experience [abstract]. Biol Blood Marrow Transplant 2008;14(2 suppl 2):Abstract 467.CrossRefGoogle Scholar
Caselli, D, Rosati, A, Faraci, M, et al. Bone Marrow Transplantation Working Group of the Associazione Italiana Ematologia Oncologia Pediatrica. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):282–5.CrossRefGoogle ScholarPubMed
Diaz-Carrasco, MS, Olmos, R, Blanquer, M, et al. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm. 2013;35(3):339–43.CrossRefGoogle ScholarPubMed
Caselli, D, Ziino, O, Bartoli, A, et al. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant. 2008;42(2):135–6.CrossRefGoogle ScholarPubMed
Yazal Erdem, A, Azık, F, Tavil, B, et al. Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy. Pediatr Transplant. 2014;18(4):412–3.CrossRefGoogle ScholarPubMed
Ogden, CL, Carroll, MD, Kit, BK, Flegal, KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14.CrossRefGoogle ScholarPubMed
Griggs, JJ, Mangu, PB, Anderson, H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2012;30:1553–61.CrossRefGoogle ScholarPubMed
Bubalo, J, Carpenter, PA, Majhail, N, et al. Conditioning chemotherapy dose adjustment in obese patients: A review and position statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. Biol Blood Marrow Transplant. 2014;20: 600–16.CrossRefGoogle ScholarPubMed
Weiss, BM, Vogl, DT, Berger, NA, Stadtmauer, EA, Lazarus, HM. Trimming the fat: obesity and hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48: 1152–60.CrossRefGoogle ScholarPubMed
Cutler, C, Kim, HT, Hochberg, E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):328–36.Google ScholarPubMed
Cutler, C, Li, S, Ho, VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7):3108–14.CrossRefGoogle ScholarPubMed
Cutler, C, Logan, B, Nakamura, R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372–7.CrossRefGoogle ScholarPubMed
Rodriguez, R, Nakamura, R, Palmer, JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098–105.CrossRefGoogle ScholarPubMed
Pidala, J, Kim, J, Jim, H, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012:97(12):1882–9.CrossRefGoogle ScholarPubMed
Pidala, J, Tomblyn, M, Nishihori, T, et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011;96(9):1351–6.CrossRefGoogle ScholarPubMed
Li, H, Mager, DE, Sandmaier, BM, et al. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol. 2013;53(4):393–402.CrossRefGoogle ScholarPubMed
Kim, H, Long-Boyle, J, Rydholm, N, et al. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J Clin Pharmacol. 2012;52(11):1665–75.CrossRefGoogle Scholar
McDermott, CL, Sandmaier, BM, Storer, B, et al. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1159–66.CrossRefGoogle ScholarPubMed
Giaccone, L, McCune, JS, Maris, MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005;106:4381–8.CrossRefGoogle ScholarPubMed
Royer, B, Larosa, F, Legrand, F, et al. Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. Biol Blood Marrow Transplant. 2009;15(9):1134–9.CrossRefGoogle ScholarPubMed
Harnicar, S, Ponce, DM, Hilden, P, et al. Intensified mycophenolate mofetil dosing and higher mycophenolic acid trough levels reduce severe acute graft-versus-host disease after double-unit cord blood transplantation. Biol Blood Marrow Transplant. 2015;21(5):920–5.CrossRefGoogle ScholarPubMed
Aisa, Y, Mori, T, Nakazato, T, et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. Transplantation. 2005;80(8):1046–50.CrossRefGoogle ScholarPubMed
Woo, M, Przepiorka, D, Ippoliti, C, et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997;20(12):1095–8.CrossRefGoogle ScholarPubMed
Saif, MW. Management of hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol. 2008;6(5):243–8.Google ScholarPubMed
Atsmon, J, Dolev, E. Drug-induced hypomagnesaemia : scope and management. Drug Saf. 2005;28(9):763–88.CrossRefGoogle ScholarPubMed
Gholaminezhad, S, Hadjibabaie, M, Gholami, K, et al. Pattern and associated factors of potential drug-drug interactions in both pre- and early post-hematopoietic stem cell transplantation stages at a referral center in the Middle East. Ann Hematol. 2014;93(11):1913–22.CrossRefGoogle Scholar
Cornely, OA, Maertens, J, Winston, DJ, et al. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.CrossRefGoogle ScholarPubMed
Ullmann, AJ, Lipton, JH, Vesole, DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.CrossRefGoogle ScholarPubMed
Marks, DI, Pagliuca, A, Kibbler, CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic hematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–27.CrossRefGoogle Scholar
Wingard, JR, Carter, SL, Walsh, TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–18.CrossRefGoogle ScholarPubMed
Slavin, MA, Osborne, B, Adams, R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.CrossRefGoogle ScholarPubMed
Marr, KA, Seidel, K, Slavin, MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2006;96:2055–61.Google Scholar
Marr, KA, Crippa, F, Leisenring, W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–33.CrossRefGoogle ScholarPubMed
Winston, DJ, Maziarz, RT, Chandrasekar, PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705–13.CrossRefGoogle ScholarPubMed
Goodman, JL, Winston, DJ, Greenfield, RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.CrossRefGoogle ScholarPubMed
van Burik, JA, Ratanatharathorn, V, Stepan, DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.CrossRefGoogle ScholarPubMed
Tomblyn, M, Chiller, T, Einsele, H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.CrossRefGoogle ScholarPubMed
Shayani, S, Palmer, J, Stiller, T, et al. Thrombotic microangiopathy associated with sirolimus levels following allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based GVHD prophylaxis. Biol Blood Marrow Transplant. 2013;19(2):298–304.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×